Drug Type Antibody drug conjugate (ADC) |
Synonyms Brentuximab, Brentuximab Vedotin (Genetical Recombinatin), Brentuximab vedotin (genetical recombination) (JAN) + [20] |
Target |
Action modulators, inhibitors |
Mechanism CD30 modulators(Tumor necrosis factor receptor superfamily member 8 modulators), Tubulin inhibitors, Antibody-dependent cellular phagocytosis (ADCP) effects |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (19 Aug 2011), |
RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (South Korea) |



| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D09587 | Brentuximab Vedotin |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | United States | 11 Feb 2025 | |
| High grade B-cell lymphoma | United States | 11 Feb 2025 | |
| CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma | Japan | 24 Nov 2023 | |
| Classical Hodgkin's Lymphoma | United States | 09 Nov 2017 | |
| Mycosis Fungoides | United States | 09 Nov 2017 | |
| Primary Cutaneous Anaplastic Large Cell Lymphoma | United States | 09 Nov 2017 | |
| Cutaneous T-Cell Lymphoma | Australia | 20 Dec 2013 | |
| Peripheral T-Cell Lymphoma | Australia | 20 Dec 2013 | |
| CD-30 positive Peripheral T-Cell Lymphoma | South Korea | 16 May 2013 | |
| CD30+ Hodgkin's Lymphoma | European Union | 25 Oct 2012 | |
| CD30+ Hodgkin's Lymphoma | Iceland | 25 Oct 2012 | |
| CD30+ Hodgkin's Lymphoma | Liechtenstein | 25 Oct 2012 | |
| CD30+ Hodgkin's Lymphoma | Norway | 25 Oct 2012 | |
| CD30-Positive Cutaneous T-Cell Lymphoma | European Union | 25 Oct 2012 | |
| CD30-Positive Cutaneous T-Cell Lymphoma | Iceland | 25 Oct 2012 | |
| CD30-Positive Cutaneous T-Cell Lymphoma | Liechtenstein | 25 Oct 2012 | |
| CD30-Positive Cutaneous T-Cell Lymphoma | Norway | 25 Oct 2012 | |
| Recurrent Anaplastic Large Cell Lymphoma | European Union | 25 Oct 2012 | |
| Recurrent Anaplastic Large Cell Lymphoma | Iceland | 25 Oct 2012 | |
| Recurrent Anaplastic Large Cell Lymphoma | Liechtenstein | 25 Oct 2012 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| CD-30 positive Lymphoma | Phase 3 | - | 01 Jan 2024 | |
| Primary mediastinal large B-cell lymphoma recurrent | Phase 3 | - | 01 Jan 2024 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | United States | 20 Aug 2020 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | Australia | 20 Aug 2020 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | Belgium | 20 Aug 2020 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | Canada | 20 Aug 2020 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | Czechia | 20 Aug 2020 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | Denmark | 20 Aug 2020 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | France | 20 Aug 2020 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | Italy | 20 Aug 2020 |
Phase 2 | 30 | oplurwbxpk(wghtvvtqpk) = xvzfuqqryl gigaqavibr (mvtiymmhus ) View more | Positive | 12 Dec 2026 | |||
Phase 1 | 15 | ksofiyyeyx(ixnkevwvgm) = grade 3 fatigue xdqohbyfue (vbvwmftbsb ) View more | Positive | 12 Dec 2026 | |||
Not Applicable | 638 | Brentuximab vedotin plus CHP (BV-CHP) | lzarfqnvnt(qkgxgrysij) = gxfzfruula luxnvbjvum (jitcrravtf ) View more | Positive | 12 Dec 2026 | ||
CHOP | lzarfqnvnt(qkgxgrysij) = hquupyjtvc luxnvbjvum (jitcrravtf ) View more | ||||||
Not Applicable | 121 | BV-CHP | hffqiyloxs(ibzqofmcta): HR = 0.84 (95.0% CI, 0.37 - 1.91) View more | Positive | 12 Dec 2026 | ||
CHOP | |||||||
Not Applicable | Classical Hodgkin's Lymphoma First line | 8,947 | Nivo-AVD | bjbwayomqh(dqibdzcwqu): HR = 0.89 (95.0% CI, 0.47 - 1.68) View more | Positive | 12 Dec 2026 | |
eBEACOPP | |||||||
Not Applicable | 121 | BV-free chemotherapy induction | accmivyhqd(vbnrlgvlux) = Grade 3 or 4 adverse events were predominantly hematologic. In the BV plus chemotherapy and chemotherapy-alone groups, the incidences of grade 3 or 4 neutropenia were 42.6% and 53.1%, respectively; febrile neutropenia occurred in 13.4% and 18.8%; and anemia occurred in 30.5% and 53.1%. The reported grade 3 or 4 nonhematologic adverse events were uncommon. ntilndslwi (pvflhclsrw ) View more | Positive | 12 Dec 2026 | ||
Brentuximab vedotin plus chemotherapy induction | |||||||
Not Applicable | 181 | CAR-T-cells | dnzyejlehh(xjbzkvgyps) = yefzhxuswl pkaxbdyrsd (nevlojnstl ) View more | Positive | 12 Dec 2026 | ||
CPI treatment (PEL) | dnzyejlehh(xjbzkvgyps) = rlcprrdocd pkaxbdyrsd (nevlojnstl ) | ||||||
Phase 3 | 67 | hkkqtsited(vvlezqnthy) = sybasqgjaf ogwjrhxcxo (smsitgkdog, 5.1 - 31.5) View more | Positive | 12 Dec 2026 | |||
hkkqtsited(vvlezqnthy) = ydqocazlgn ogwjrhxcxo (smsitgkdog, 3.6 - 11.7) View more | |||||||
Not Applicable | 98 | mnmmfvdbmc(udwcwbryca) = sipfzeogcl xijriepsms (epwaocihsb ) View more | Positive | 12 Dec 2026 | |||
Phase 2 | Cutaneous T-Cell Lymphoma CD30-positive | 14 | Pembrolizumab plus brentuximab vedotin | fubifikyqf(miakacafgw) = jizseaphfc fzvdtrnjtj (cdmxvpkhpc, 23.0 - 77.0) View more | Positive | 12 Dec 2026 |






